These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 28472597)

  • 1. Golimumab for the treatment of ulcerative colitis.
    Flamant M; Paul S; Roblin X
    Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
    Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
    Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis.
    Galván-Banqueri M; Vega-Coca MD; Castillo-Muñoz MA; Beltrán Calvo C; Molina López T
    Farm Hosp; 2015 Mar; 39(2):80-91. PubMed ID: 25817087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biologics of ulcerative colitis.
    Macaluso FS; Renna S; Orlando A; Cottone M
    Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
    Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
    Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
    Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golimumab in inflammatory bowel diseases: present and future scenarios.
    Dragoni G; Le Grazie M; Orlandini B; Rogai F
    Clin J Gastroenterol; 2019 Feb; 12(1):1-9. PubMed ID: 30206776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy options for ulcerative colitis.
    Chaparro M; Gisbert JP
    Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab for moderate to severe ulcerative colitis.
    Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.